These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
111 related articles for article (PubMed ID: 23006942)
1. Has single-agent rituximab replaced watch-and-wait for a patient with asymptomatic low-grade follicular lymphoma? Lowry L; Ardeshna KM Cancer J; 2012; 18(5):390-5. PubMed ID: 23006942 [TBL] [Abstract][Full Text] [Related]
2. Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trial. Ardeshna KM; Qian W; Smith P; Braganca N; Lowry L; Patrick P; Warden J; Stevens L; Pocock CF; Miall F; Cunningham D; Davies J; Jack A; Stephens R; Walewski J; Ferhanoglu B; Bradstock K; Linch DC Lancet Oncol; 2014 Apr; 15(4):424-35. PubMed ID: 24602760 [TBL] [Abstract][Full Text] [Related]
3. Rituximab maintenance therapy for follicular lymphoma: no better than watchful waiting. Prescrire Int; 2012 Mar; 21(125):62. PubMed ID: 22428182 [TBL] [Abstract][Full Text] [Related]
4. Rituximab for the treatment of relapsed or refractory stage III or IV follicular non-Hodgkin's lymphoma. Boland A; Bagust A; Hockenhull J; Davis H; Chu P; Dickson R Health Technol Assess; 2009 Sep; 13 Suppl 2():41-8. PubMed ID: 19804688 [TBL] [Abstract][Full Text] [Related]
5. Frontline rituximab monotherapy induction versus a watch and wait approach for asymptomatic advanced-stage follicular lymphoma: A cost-effectiveness analysis. Prica A; Chan K; Cheung M Cancer; 2015 Aug; 121(15):2637-45. PubMed ID: 25877511 [TBL] [Abstract][Full Text] [Related]
6. Has the time to come leave the "watch-and-wait" strategy in newly diagnosed asymptomatic follicular lymphoma patients? Rueda A; Casanova M; Redondo M; Pérez-Ruiz E; Medina-Pérez A BMC Cancer; 2012 May; 12():210. PubMed ID: 22650448 [TBL] [Abstract][Full Text] [Related]
7. Rituximab maintenance therapy of relapsed or refractory follicular lymphoma, with longer follow-up: no proven impact on survival. Prescrire Int; 2012 Mar; 21(125):63. PubMed ID: 22428183 [TBL] [Abstract][Full Text] [Related]
8. Is there a role for "watch and wait" in follicular lymphoma in the rituximab era? Kahl B Hematology Am Soc Hematol Educ Program; 2012; 2012():433-8. PubMed ID: 23233615 [TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of rituximab in follicular lymphoma. Johnston KM; Bolbocean C; Connors J; Peacock S Expert Rev Pharmacoecon Outcomes Res; 2012 Oct; 12(5):569-77. PubMed ID: 23140274 [TBL] [Abstract][Full Text] [Related]
10. Watchful waiting in low-tumor burden follicular lymphoma in the rituximab era: results of an F2-study database. Solal-Céligny P; Bellei M; Marcheselli L; Pesce EA; Pileri S; McLaughlin P; Luminari S; Pro B; Montoto S; Ferreri AJ; Deconinck E; Milpied N; Gordon LI; Federico M J Clin Oncol; 2012 Nov; 30(31):3848-53. PubMed ID: 23008294 [TBL] [Abstract][Full Text] [Related]
11. Rituximab therapy for patients with newly diagnosed, advanced-stage, follicular grade I non-Hodgkin's lymphoma: a phase II trial in the North Central Cancer Treatment Group. Witzig TE; Vukov AM; Habermann TM; Geyer S; Kurtin PJ; Friedenberg WR; White WL; Chalchal HI; Flynn PJ; Fitch TR; Welker DA J Clin Oncol; 2005 Feb; 23(6):1103-8. PubMed ID: 15657404 [TBL] [Abstract][Full Text] [Related]
12. Maintenance therapy for low-grade lymphomas: has the time come? Cartron G; Solal-Céligny P Curr Opin Oncol; 2007 Sep; 19(5):425-32. PubMed ID: 17762565 [TBL] [Abstract][Full Text] [Related]
13. 'Watch and wait' as initial management for patients with follicular lymphomas: still a viable strategy? Hagemeister FB BioDrugs; 2012 Dec; 26(6):363-76. PubMed ID: 23057946 [TBL] [Abstract][Full Text] [Related]
14. Rituximab and its role as maintenance therapy in non-Hodgkin lymphoma. Collins-Burow B; Santos ES Expert Rev Anticancer Ther; 2007 Mar; 7(3):257-73. PubMed ID: 17338647 [TBL] [Abstract][Full Text] [Related]
15. Rituximab for the treatment of follicular lymphoma. Cheah CY; Lingaratnam S; Seymour JF Future Oncol; 2013 Sep; 9(9):1283-98. PubMed ID: 23980675 [TBL] [Abstract][Full Text] [Related]
16. Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up. Czuczman MS; Weaver R; Alkuzweny B; Berlfein J; Grillo-López AJ J Clin Oncol; 2004 Dec; 22(23):4711-6. PubMed ID: 15483015 [TBL] [Abstract][Full Text] [Related]
17. Current treatment of follicular and low-grade non-Hodgkin's lymphoma. Linch D Anticancer Drugs; 2001 Jun; 12 Suppl 2():S5-9. PubMed ID: 11508934 [TBL] [Abstract][Full Text] [Related]
18. Update on front-line therapy for follicular lymphoma: chemo-immunotherapy with rituximab and survival. Turturro F Expert Rev Anticancer Ther; 2007 Jul; 7(7):959-65. PubMed ID: 17627454 [TBL] [Abstract][Full Text] [Related]
20. Maximizing therapeutic benefit of rituximab: maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin's lymphoma--a randomized phase II trial of the Minnie Pearl Cancer Research Network. Hainsworth JD; Litchy S; Shaffer DW; Lackey VL; Grimaldi M; Greco FA J Clin Oncol; 2005 Feb; 23(6):1088-95. PubMed ID: 15657401 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]